Results 221 to 230 of about 334,593 (294)

Daunorubicin‐45 Vs. Daunorubicin‐60 for Induction in Intermediate‐Age Patients of AML: Results From a Randomized Trial

Cancer Science, EarlyView.
Daunorubicin dose escalation from 45 to 60 mg/m2 provides no clinical benefit for AML patients aged 55–65. A dose of 45 mg/m2 should remain the preferred regimen for this population. ABSTRACT Daunorubicin dose optimization remains crucial for AML treatment.
Chunlin Zhou, Le Li, Yan Li, Kaiqi Liu, Yuntao Liu, Dong Lin, Benfa Gong, Guangji Zhang, Xiaoyuan Gong, Qiuyun Fang, Bingcheng Liu, Shaowei Qiu, Ying Wang, Hui Wei, Yingchang Mi, Jianxiang Wang   +15 more
wiley   +1 more source

Targeted Therapy in Acute Myeloid Leukemia: Current Approaches and Novel Directions. [PDF]

J Pers Med
Ko KH, Gelfer R, Wheat JC, Cai SF.
europepmc   +1 more source

An Immune Dysfunction Signature Score Predicts Survival in MDS Patients: Insights From a Longitudinal, Multicenter Study

Cancer Science, EarlyView.
An immune dysfunction score (IDS) provides independent prognostic information in MDS and CMML, complements current risk models, mirrors disease changes, and reflects underlying immune impairment. IDS may also highlight therapeutic sensitivities, supporting its use as a practical biomarker for risk stratification and clinical follow‐up.
Yu‐Hung Wang, Carmelo Gurnari, Valeria Visconte, Arda Durmaz, Luca Guarnera, Wan‐Hsuan Lee, Chi‐Yuan Yao, Andres Jerez, Kristian Gurashi, Kiran Batta, Hsin‐An Hou, Wen‐Chien Chou, Mrinal S. Patnaik, Jaroslaw Maciejewski, Daniel H. Wiseman, Chien‐Chin Lin, Hwei‐Fang Tien   +16 more
wiley   +1 more source

Landscape of circular RNAs in acute myeloid leukemia and their clinical significance. [PDF]

NPJ Precis Oncol
Nguyen TH, Nguyen MH, Nguyen HN, Erkers T, Östling P, Bohlin A, Österroos A, Jafari R, Orre LM, Lehtiö J, Lehmann S, Kallioniemi O, Pawitan Y, Vu TN.   +13 more
europepmc   +1 more source

Multiplexed Transcriptomics for Screening Drug Combinations and Defining the Mechanism of Action of HCC Therapeutics at Single‐Cell Resolution

Cell Proliferation, EarlyView.
We designed a framework for screening clinical drug combinations with anti‐hepatocellular carcinoma (HCC) activity, comprising four parts: primary screening, single‐cell screening, functional validation, and mechanism research. High‐throughput single‐cell screening identifies HY (HHT and YM155) as a potent anti‐HCC drug combination, validated by in ...
Mengmeng Jiang, Haide Chen, Guoxia Wen, Yuqing Mei, Wenzhao Zhou, Bin Xu, Tingyue Zhang, Guangyan Li, Junqing Wu, Xiaoping Han, Xudong Fu, Guoji Guo, Jingjing Wang   +12 more
wiley   +1 more source

Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR), With del(5q) and Double Minutes Containing Chromosomal Segment 11q24 Leading to Amplification and Expression of FLI1. [PDF]

Case Rep Hematol
Hiya S, Tripodi J, Mascarenhas J, Florea AD, Najfeld V.   +4 more
europepmc   +1 more source

Recombinant zoster vaccine induces superior immunogenicity compared with live varicella vaccine in allogeneic haematopoietic stem cell transplantation recipients

British Journal of Haematology, EarlyView.
Takaaki Ono, Takashi Okada, Ryo Ikeda, Mitsuru Yamashita, Katsumi Koyauchi, Fumisato Takagi, Miwa Adachi, Tomonari Takemura, Kozue Mitsui, Yasuyuki Nagata   +9 more
wiley   +1 more source

Preclinical advances and mechanistic insights of CAR-T therapy for acute myeloid leukemia: from target iteration to microenvironment regulation. [PDF]

Ann Med
Xiao Y, Liu L, Liu S, Wang L, Tian J, Shao Z, Shi J, Cui C.   +7 more
europepmc   +1 more source

Comparative efficacy of different therapeutic approaches in treatment naïve FLT3-mutated AML eligible for intensive chemotherapy: a Bayesian network meta-analysis of randomized trials. [PDF]

Ann Hematol
Bruzzese A, Lofaro D, Martino EA, Mendicino F, Labanca C, Caserta S, Lucia E, Olivito V, Amodio N, Morabito F, Vigna E, Gentile M.   +11 more
europepmc   +1 more source